Q3 results: Lupin reports ₹152 cr loss on one-time provisioning for litigation expenses

PTI New Delhi | Updated on February 06, 2019 Published on February 06, 2019

Lupin’s net profit before exceptional items for the third quarter stood at Rs 190.5 crore

Drug major Lupin on Wednesday posted a loss of Rs 151.75 crore for December quarter 2018, on account of one-time provisioning of Rs 342.22 crore related to a litigation over blood pressure lowering drug Perindopril in Europe.

The Mumbai-based firm had posted a net profit of Rs 221.73 crore in the October-December period of previous fiscal.

Income from operations rose to Rs 4,377.94 crore in the period under review as compared with Rs 3,900.36 crore in the year-ago quarter, Lupin said in a statement.

On December 12, 2018, the General Court of the European Union (EU) delivered its judgment concerning Lupin’s appeal against the European Commission’s 2014 decision in a litigation related to Perindopril.

The General Court upheld the EC’s decision holding Lupin liable to pay a fine of 40 million euros.

“Considering that the matter was not settled in favour of the company, provision of 42.8 million euros (Rs 342.22 crore) has been made including interest of 2.8 million euros (Rs 22.27 crore) which is disclosed as an exceptional item,” Lupin said.

The company intends to appeal against this decision before the European Court of Justice, it added.

In 2014, Lupin and Unichem Laboratories were among six global drug makers on which the European regulator had imposed a collective fine of 427.7 million euros for striking deals to prevent entry of cheaper versions of Perindopril in the EU.

The company’s net profit before exceptional items for the third quarter stood at Rs 190.5 crore.

Commenting on the results, Lupin Managing Director Nilesh Gupta said after witnessing a tough first half, the company is now starting to see growth in the United States (US).

“The growth momentum in the US will continue into the next quarter as we are on track with important launches like Levothyroxine and Ranolazine...We are also on track to deliver on our cost optimisation efforts and expect meaningful benefit next fiscal onwards,” he added.

Lupin said its North America sales for third quarter stood at Rs 1,417.4 crore as compared with Rs 1,432.1 crore during the same period of previous fiscal.

In India, the company’s formulation sales increased 11.4 per cent to Rs 1,190.2 crore as compared with Rs 1,068.8 crore in the October-December period of 2017-18.

Shares of the company settled at Rs 841.95 apiece, up 0.56 per cent from the previous close, on the Bombay Stock Exchange (BSE).

Published on February 06, 2019
This article is closed for comments.
Please Email the Editor